# CT-2106 for the Second Line Treatment of Ovarian Cancer

> **NCT00291837** · PHASE2 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 40 (—)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** CT-2106

## Key facts

- **NCT ID:** NCT00291837
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-06
- **Final completion:** 2007-12
- **Target enrollment:** 40 (—)
- **Last updated:** 2010-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291837, "CT-2106 for the Second Line Treatment of Ovarian Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00291837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*